Multicenter, Open Label Phase 1 Study in Patients with Biliary Tract Cancer
Latest Information Update: 13 Sep 2022
At a glance
- Drugs Nivolumab (Primary) ; Cisplatin; Gemcitabine
- Indications Biliary cancer
- Focus Adverse reactions
- Sponsors Ono Pharmaceutical
- 12 Sep 2022 Status changed from active, no longer recruiting to completed.
- 19 Jan 2019 Results presented at the 2019 Gastrointestinal Cancers Symposium
- 08 May 2018 Status changed from recruiting to active, no longer recruiting.